Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets

NCT00853554 | Completed Phase 1

• 1 other identifier: 3249-02-769
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of hydromorphone 8 mg to an equivalent oral dose of a commercially available hydromorphone tablet (DILAUDID® 8 mg, Knoll Pharmaceutical Company) in a test group of healthy subjects under fasting conditions.

Conditions

Healthy

Keywords

Healthy Subjects; Bioequivalence

Outcome Measures

Primary Outcomes (1)

• Bioequivalence based on AUCt, AUCinf and Cmax

  Two-period crossover with blood samples obtained prior to and following each dose at selected times through 24 hours. Washout period between doses was 7 days.

Study Arms (2)

A

EXPERIMENTAL

Hydromorphone Hydrochloride tablet 8 mg

Drug: Hydromorphone Hydrochloride tablet 8 mg

B

ACTIVE COMPARATOR

Dilaudid® tablet 8 mg

Drug: Dilaudid® tablet 8 mg

Interventions

Hydromorphone Hydrochloride tablet 8 mg DRUG

Hydromorphone Hydrochloride tablet 8 mg, single dose fasting

A

Dilaudid® tablet 8 mg DRUG

Dilaudid® tablet 8 mg, single dose fasting

B

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or non-pregnant, non-lactating females, 18 years of age or older.
• Female subjects must be postmenopausal for at least one year, or surgically sterile, or practicing adequate non-hormonal contraception for at least 3 months prior to and for the duration of study participation. All female subjects will undergo a pregnancy test at screening and at check-in to the clinical study site for every dosing period. The results of the test must be negative for continued participation.
• Weight must be within 15% of the ideal weight for height and frame, as adopted by the Metropolitan Life Insurance Co., 1993.
• Qualifying subjects must be in good health and physical condition as determined by a screening medical history obtained within 30 days prior to study start. Subjects should not present with a history of significant past illness expected to affect the investigation.
• The normal status of subjects will be confirmed by the following procedures:
• Laboratory tests (serum chemistry, hematology, urinalysis)
• Human immunodeficiency virus (HIV), hepatitis, alcohol, and "drugs of abuse" testing will be done at screening. Results of the HIV, hepatitis, alcohol, and "drugs of abuse" tests must be negative or non-reactive for
• Electrocardiogram: A 12-lead electrocardiogram (ECG) will be obtained for all subjects. This ECG must be interpreted by appropriately trained and experienced medical personnel. A subject with an ECG that is not within normal range does not qualify, unless specifically accepted (with comment) by the investigator.
• Subjects must be able to provide written consent and agree to abide by the study requirements.

You may not qualify if:

• History of alcohol, drug, or narcotic abuse or dependence.
• Chronic use of tranquilizers, sedatives, aspirin, antibiotics, or other medications.
• History or presence of major organ dysfunction.
• History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorder capable of altering the absorption, metabolism, or elimination of drugs or constituting a risk factor when taking hydromorphone.
• History of anxiety, tension, severe agitation, psychosis, or mental depression.
• Family history or diagnosis of epilepsy or other seizure disorder.
• History of acute abdominal conditions.
• History of conditions that might contraindicate or require caution be used in the administration of hydromorphone including: renal impairment, hepatobiliary or pancreatic disease, GI obstruction, cardiac disease, obstructive pulmonary disease, acute or severe bronchial asthma, hypercarbia, elevated intracranial pressure, depleted blood volume, paralytic ileus, or allergy to hydromorphone, any opiate agonists, or naltrexone.
• Administration of any other investigational drug during the 30 days prior to enrollment into the study.
• Subjects who smoke or have a history of smoking, or use nicotine-containing products.
• Subjects who have donated blood within 30 days prior to study entry, including that withdrawn during the conduct of any other clinical study.
• Subjects presenting with acute illness.
• Subjects who have taken prescription drugs within 14 days or over-the-counter medications (including herbal preparations) within 7 days prior to dosing except for standard daily dose multivitamins.

Sponsors & Collaborators

• Mallinckrodt: lead

Study Sites (1)

Gateway Medical Research

Saint Charles, Missouri, 63301, United States

Location

MeSH Terms

Interventions

Hydromorphone

Intervention Hierarchy (Ancestors)

Morphine Derivatives; Morphinans; Opiate Alkaloids; Alkaloids; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Phenanthrenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds

Study Officials

• Herbert Neuman, MD

  Mallinckrodt

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: February 26, 2009
• First Posted: March 2, 2009
• Study Start: December 1, 2002
• Primary Completion: December 1, 2002
• Study Completion: December 1, 2002
• Last Updated: October 19, 2016

Record last verified: 2016-10

Locations

US (1)